During a survey of Group G and C streptococcal infections of humans two epidemiologically unrelated Group G streptococcal isolates were identified, one from a case of bacteremia and one from a wound infection. These isolates were atypical among this sample in that the emm gene could not be amplified from them by PCR. Biochemical characterization identified the isolates as Streptococcus canis, an organism normally associated with animal hosts. The biochemical identification was confirmed by sequencing of the 16S rRNA gene from both isolates and comparison with sequences of the S. canis type strain and other related streptococci of animals and humans. Comparative sequencing of fragments of two other housekeeping genes, sodA and mutS, confirmed that the isolates are most closely related to S. canis. The identification of two isolates of S. canis from a relatively small sample set suggests that the practice of identifying streptococci only by the Lancefield serological group may result in underestimation of the presence of S. canis in the human population.

Summary The possible association between breast cancer and oral contraceptive use before the age of 20 was investigated using Icelandic population-based information from women born after 1944. The design was a nested case-control study within a cohort, using data on duration of oral contraceptive use at young ages. The availability of oral contraceptives before the age of 20 has changed dramatically and is highly dependent on birth years, with 20% and 82% starting before the age of 20 among Icelandic users born in 1945-47 and 1963-67 respectively. The association between total duration of oral contraceptive use and breast cancer was significantly dependent on year of birth. In women born in 1951-67 (based on 81 cases), the relative risk (RR) associated with use for more than 4 years was 2.0 (95% Cl 1.1-3.7). The association disappeared when women born in 1945-50 were included (RR 1.1, 95% Cl 0.8-1.6), adding 123 cases. A significant trend of increased risk with longer duration was present only in the group born after 1950, with RR 0.9, 1.7 and 3.0 for <4 years, >4-8 years and > 8 years of use respectively. The results of this study indicate an association between breast cancer and oral contraceptive use at a young age. They also stress the importance of distinguishing between groups with different opportunities for exposure at young age.

BACKGROUNDRhesus D (RhD) incompatibility is still the most important cause of hemolytic disease of the fetus and newborn (HDFN) worldwide. The aim of this study was to investigate the incidence, causes, and consequences of anti‐D alloimmunizations in pregnancy in Iceland, prior to implementation of targeted routine antenatal anti‐D prophylaxis (RAADP) in 2018.STUDY DESIGN AND METHODSThis was a nation‐wide cohort study of 130 pregnancies affected by RhD alloimmunization in Iceland in the period from 1996 through 2015. Data were collected from transfusion medicine databases, medical records, and the Icelandic Medical Birth Register.RESULTSOf 130 RhD alloimmunizations, 80 cases (61.5%) represented new RhD immunization in the current pregnancy. Sensitization was discovered in the third trimester in 41 (51.3%) and occurred in the first pregnancy in 14 cases (17.5%). The most likely causative immunization event was the index pregnancy for 45 (56.25%), a previous pregnancy/birth for 26 (32.5%), abortion for 3 (3.75%), and unknown for 6 women (7.5%). Higher anti‐D titers were associated with shorter gestational length, cesarean sections, positive direct antiglobulin test (DAT), and severe HDFN. Intrauterine transfusion (IUT) was performed in five pregnancies (3.8%), and 35 of 132 (26.5%) live‐born neonates received treatment for HDFN; 32 received phototherapy (24.2%), 13 exchange transfusion (9.8%), and seven simple blood transfusion (5.3%).CONCLUSIONIn about half of cases, RhD alloimmunization was caused by the index pregnancy and discovered in the third trimester. Thus, the newly implemented RAADP protocol should be effective in reducing the incidence of RhD immunization in Iceland in the future.